287 related articles for article (PubMed ID: 22447153)
1. Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation.
Engelen M; Schackmann MJ; Ofman R; Sanders RJ; Dijkstra IM; Houten SM; Fourcade S; Pujol A; Poll-The BT; Wanders RJ; Kemp S
J Inherit Metab Dis; 2012 Nov; 35(6):1137-45. PubMed ID: 22447153
[TBL] [Abstract][Full Text] [Related]
2. The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy.
Ofman R; Dijkstra IM; van Roermund CW; Burger N; Turkenburg M; van Cruchten A; van Engen CE; Wanders RJ; Kemp S
EMBO Mol Med; 2010 Mar; 2(3):90-7. PubMed ID: 20166112
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
Singh J; Khan M; Singh I
J Lipid Res; 2011 Nov; 52(11):2056-69. PubMed ID: 21891797
[TBL] [Abstract][Full Text] [Related]
4. Biochemical aspects of X-linked adrenoleukodystrophy.
Kemp S; Wanders R
Brain Pathol; 2010 Jul; 20(4):831-7. PubMed ID: 20626744
[TBL] [Abstract][Full Text] [Related]
5. Impaired very long-chain acyl-CoA β-oxidation in human X-linked adrenoleukodystrophy fibroblasts is a direct consequence of ABCD1 transporter dysfunction.
Wiesinger C; Kunze M; Regelsberger G; Forss-Petter S; Berger J
J Biol Chem; 2013 Jun; 288(26):19269-79. PubMed ID: 23671276
[TBL] [Abstract][Full Text] [Related]
6. Abcd2 is a strong modifier of the metabolic impairments in peritoneal macrophages of ABCD1-deficient mice.
Muneer Z; Wiesinger C; Voigtländer T; Werner HB; Berger J; Forss-Petter S
PLoS One; 2014; 9(9):e108655. PubMed ID: 25255441
[TBL] [Abstract][Full Text] [Related]
7. Enzymatic characterization of ELOVL1, a key enzyme in very long-chain fatty acid synthesis.
Schackmann MJ; Ofman R; Dijkstra IM; Wanders RJ; Kemp S
Biochim Biophys Acta; 2015 Feb; 1851(2):231-7. PubMed ID: 25499606
[TBL] [Abstract][Full Text] [Related]
8. Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes.
Singh J; Khan M; Singh I
Biochim Biophys Acta; 2013 Apr; 1831(4):747-58. PubMed ID: 23318275
[TBL] [Abstract][Full Text] [Related]
9. Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy.
Netik A; Forss-Petter S; Holzinger A; Molzer B; Unterrainer G; Berger J
Hum Mol Genet; 1999 May; 8(5):907-13. PubMed ID: 10196381
[TBL] [Abstract][Full Text] [Related]
10. ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.
Baarine M; Beeson C; Singh A; Singh I
J Neurochem; 2015 May; 133(3):380-96. PubMed ID: 25393703
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy.
McGuinness MC; Zhang HP; Smith KD
Mol Genet Metab; 2001; 74(1-2):256-63. PubMed ID: 11592822
[TBL] [Abstract][Full Text] [Related]
12. Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy.
McGuinness MC; Lu JF; Zhang HP; Dong GX; Heinzer AK; Watkins PA; Powers J; Smith KD
Mol Cell Biol; 2003 Jan; 23(2):744-53. PubMed ID: 12509471
[TBL] [Abstract][Full Text] [Related]
13. Bezafibrate for X-linked adrenoleukodystrophy.
Engelen M; Tran L; Ofman R; Brennecke J; Moser AB; Dijkstra IM; Wanders RJ; Poll-The BT; Kemp S
PLoS One; 2012; 7(7):e41013. PubMed ID: 22911730
[TBL] [Abstract][Full Text] [Related]
14. [Adrenoleukodystrophy: molecular pathogenesis and development of therapeutic agents].
Morita M
Yakugaku Zasshi; 2007 Jul; 127(7):1059-64. PubMed ID: 17603264
[TBL] [Abstract][Full Text] [Related]
15. Astrocytes and mitochondria from adrenoleukodystrophy protein (ABCD1)-deficient mice reveal that the adrenoleukodystrophy-associated very long-chain fatty acids target several cellular energy-dependent functions.
Kruska N; Schönfeld P; Pujol A; Reiser G
Biochim Biophys Acta; 2015 May; 1852(5):925-36. PubMed ID: 25583114
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy.
Weinhofer I; Forss-Petter S; Zigman M; Berger J
Hum Mol Genet; 2002 Oct; 11(22):2701-8. PubMed ID: 12374760
[TBL] [Abstract][Full Text] [Related]
17. X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes.
Weber FD; Wiesinger C; Forss-Petter S; Regelsberger G; Einwich A; Weber WH; Köhler W; Stockinger H; Berger J
Hum Mol Genet; 2014 May; 23(10):2542-50. PubMed ID: 24363066
[TBL] [Abstract][Full Text] [Related]
18. Substrate specificity overlap and interaction between adrenoleukodystrophy protein (ALDP/ABCD1) and adrenoleukodystrophy-related protein (ALDRP/ABCD2).
Genin EC; Geillon F; Gondcaille C; Athias A; Gambert P; Trompier D; Savary S
J Biol Chem; 2011 Mar; 286(10):8075-8084. PubMed ID: 21209459
[TBL] [Abstract][Full Text] [Related]
19. Suppression of peroxisomal membrane protein defects by peroxisomal ATP binding cassette (ABC) proteins.
Braiterman LT; Zheng S; Watkins PA; Geraghty MT; Johnson G; McGuinness MC; Moser AB; Smith KD
Hum Mol Genet; 1998 Feb; 7(2):239-47. PubMed ID: 9425230
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of mutated and normal adrenoleukodystrophy protein reduces protein function: implications for gene therapy of X-linked adrenoleukodystrophy.
Unterrainer G; Molzer B; Forss-Petter S; Berger J
Hum Mol Genet; 2000 Nov; 9(18):2609-16. PubMed ID: 11063720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
